Chronic Lymphocytic Leukemia
December 2022 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Chronic Lymphocytic Leukemia abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Chronic Lymphocytic Leukemia. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Chronic Lymphocytic Leukemia. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Chronic Lymphocytic Leukemia every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Chronic lymphocytic leukemia treatment algorithm 2022.
Authors:Hampel PJ, Parikh SA
Institution:Division of Hematology, Mayo Clinic, Rochester, MN, USA. parikh.sameer@mayo.edu.
Journal:Blood Cancer J. 2022 Nov 29;12(11):161. doi: 10.1038/s41408-022-00756-9.

2:How Have Targeted Agents Changed the Treatment Landscape for Elderly Patients with CLL?
Authors:Rhodes JM, Barrientos JC, Rai KR
Institution:Division of Hematology-Oncology, Department of Medicine at Zucker School of Medicine at Hofstra/Northwell, CLL Research and Treatment Center, 410 Lakeville Road, Suite 212, Lake Success, NY, 11042, USA. jrhodes3@northwell.edu.
Journal:Curr Oncol Rep. 2022 Dec;24(12):1705-1713. doi: 10.1007/s11912-022-01322-z. Epub 2022 Nov 5.

3:Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features.
Authors:Robbe P, Ridout KE, Vavoulis DV, Dréau H, Kinnersley B, Denny N, Chubb D, Appleby N, Cutts A, Cornish AJ, Lopez-Pascua L, Clifford R, Burns A, Stamatopoulos B, Cabes M, Alsolami R, Antoniou P, Oates M, Cavalieri D, Gibson J, Prabhu AV, Schwessinger R, Jennings D, James T, Maheswari U, Duran-Ferrer M, Carninci P, Knight SJL, Månsson R, Hughes J, Davies J, Ross M, Bentley D, Strefford JC, Devereux S, Pettitt AR, Hillmen P, Caulfield MJ, Houlston RS, Martín-Subero JI, Schuh A
Institution:Department of Oncology, University of Oxford, Oxford, UK. anna.schuh@oncology.ox.ac.uk.
Journal:Nat Genet. 2022 Nov;54(11):1675-1689. doi: 10.1038/s41588-022-01211-y. Epub 2022 Nov 4.

4:Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China.
Authors:Gu D, Li J, Miao Y
Institution:Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing, Jiangsu, China.
Journal:Expert Opin Pharmacother. 2022 Dec;23(18):1979-1986. doi: 10.1080/14656566.2022.2144218. Epub 2022 Nov 11.

5:Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study.
Authors:Deering KL, Sundaram M, Harshaw Q, Trudeau J, Barrientos JC
Institution:EPI-Q, Inc., Oak Brook, Illinois, United States of America.; Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States of America.
Journal:PLoS One. 2022 Oct 6;17(10):e0270291. doi: 10.1371/journal.pone.0270291. eCollection 2022.

6:Management of relapsed/refractory Chronic Lymphocytic Leukemia.
Authors:Woyach JA
Institution:Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Journal:Am J Hematol. 2022 Nov;97 Suppl 2:S11-S18. doi: 10.1002/ajh.26683.

7:Management of front line chronic lymphocytic leukemia.
Authors:Kutsch N, Fink AM, Fischer K
Institution:Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne, Duesseldorf and German CLL Study Group, University of Cologne, Cologne, Germany.
Journal:Am J Hematol. 2022 Nov;97 Suppl 2:S3-S10. doi: 10.1002/ajh.26677.

8:Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib.
Authors:Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Chanan-Khan AA, Kenderian SS, Muchtar E, Wang Y, Ailawadhi S, Koehler AB, Parrondo R, Schwager SM, Sher T, Hanson CA, Shi M, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA
Institution:Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. parikh.sameer@mayo.edu.
Journal:Blood Cancer J. 2022 Sep 1;12(9):124. doi: 10.1038/s41408-022-00721-6.

9:Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.
Authors:Antic D, Milic N, Chatzikonstantinou T, Scarfò L, Otasevic V, Rajovic N, Allsup D, Alonso Cabrero A, Andres M, Baile Gonzales M, Capasso A, Collado R, Cordoba R, Cuéllar-García C, Correa JG, De Paoli L, De Paolis MR, Del Poeta G, Dimou M, Doubek M, Efstathopoulou M, El-Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Lopez-Garcia A, García-Marco JA, García-Serra R, Gentile M, Gimeno E, da Silva MG, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Itchaki G, Jaksic O, Janssens A, Kalashnikova OB, Kalicińska E, Kater AP, Kersting S, Koren-Michowitz M, Labrador J, Lad D, Laurenti L, Fresa A, Levin MD, Mayor Bastida C, Malerba L, Marasca R, Marchetti M, Marquet J, Mihaljevic B, Milosevic I, Mirás F, Morawska M, Motta M, Munir T, Murru R, Nunes R, Olivieri J, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Reda G, Rigolin GM, Shrestha A, Šimkovič M, Smirnova S, Špaček M, Sportoletti P, Stanca O, Stavroyianni N, Te Raa D, Tomic K, Tonino S, Trentin L, Van Der Spek E, van Gelder M, Varettoni M, Visentin A, Vitale C, Vukovic V, Wasik-Szczepanek E, Wróbel T, Segundo LYS, Yassin M, Coscia M, Rambaldi A, Montserrat E, Foà R, Cuneo A, Carrier M, Ghia P, Stamatopoulos K
Institution:Lymphoma Center, Clinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia. darko.antic1510976@gmail.com.; Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.
Journal:J Hematol Oncol. 2022 Aug 26;15(1):116. doi: 10.1186/s13045-022-01333-0.

10:Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia.
Authors:Perutelli F, Montalbano MC, Boccellato E, Coscia M, Vitale C
Institution:University Division of Hematology, A.O.U. Citta della Salute e della Scienza di Torino.
Journal:Curr Opin Oncol. 2022 Nov 1;34(6):757-767. doi: 10.1097/CCO.0000000000000897. Epub 2022 Aug 22.

11:CD38 as a multifaceted immunotherapeutic target in CLL.
Authors:Paulus A, Malavasi F, Chanan-Khan A
Institution:Department of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL, USA.
Journal:Leuk Lymphoma. 2022 Oct;63(10):2265-2275. doi: 10.1080/10428194.2022.2090551. Epub 2022 Aug 17.

12:Approved and emerging Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Authors:Hatashima A, Karami M, Shadman M
Institution:Department of Pharmacy, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Journal:Expert Opin Pharmacother. 2022 Sep;23(13):1545-1557. doi: 10.1080/14656566.2022.2113384. Epub 2022 Aug 22.

13:Detection of early seeding of Richter transformation in chronic lymphocytic leukemia.
Authors:Nadeu F, Royo R, Massoni-Badosa R, Playa-Albinyana H, Garcia-Torre B, Duran-Ferrer M, Dawson KJ, Kulis M, Diaz-Navarro A, Villamor N, Melero JL, Chapaprieta V, Dueso-Barroso A, Delgado J, Moia R, Ruiz-Gil S, Marchese D, Giró A, Verdaguer-Dot N, Romo M, Clot G, Rozman M, Frigola G, Rivas-Delgado A, Baumann T, Alcoceba M, González M, Climent F, Abrisqueta P, Castellví J, Bosch F, Aymerich M, Enjuanes A, Ruiz-Gaspà S, López-Guillermo A, Jares P, Beà S, Capella-Gutierrez S, Gelpí JL, López-Bigas N, Torrents D, Campbell PJ, Gut I, Rossi D, Gaidano G, Puente XS, Garcia-Roves PM, Colomer D, Heyn H, Maura F, Martín-Subero JI, Campo E
Institution:Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. nadeu@recerca.clinic.cat.; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. ecampo@clinic.cat.
Journal:Nat Med. 2022 Aug;28(8):1662-1671. doi: 10.1038/s41591-022-01927-8. Epub 2022 Aug 11.

14:Efficacy and safety of phosphatidylinositol 3-kinase inhibitors in patients with chronic lymphocytic leukemia: a meta-analysis and systematic review.
Authors:Wen Y, Meng L, Zhang X, Gao Q
Institution:Department of Basic Medicine, Center of Translational Medicine, Jiangsu Key Laboratory of Molecular Medicine, Nanjing University Medical School, Nanjing, Jiangsu, China.
Journal:Expert Rev Hematol. 2022 Sep;15(9):849-856. doi: 10.1080/17474086.2022.2110062. Epub 2022 Aug 9.

15:Practical management of chronic lymphocytic leukemia with acalabrutinib.
Authors:Kuss B, Nagarajan C, Hsieh WS, Cheah CY
Institution:Molecular Medicine and Genetics, Flinders University, Adelaide, SA, Australia.; University of Western Australia Medical School, University of Western Australia, Perth, WA, Australia.
Journal:Leuk Lymphoma. 2022 Dec;63(12):2785-2794. doi: 10.1080/10428194.2022.2098289. Epub 2022 Jul 19.

16:Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance.
Authors:Omi A, Nomura F, Tsujioka S, Fujino A, Akizuki R
Institution:Medical Affairs Division, Janssen Pharmaceutical K.K., Tokyo, Japan.
Journal:J Clin Exp Hematop. 2022 Sep 28;62(3):136-146. doi: 10.3960/jslrt.22002. Epub 2022 Jul 12.

17:International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL.
Authors:Awan FT, Addison D, Alfraih F, Baratta SJ, Campos RN, Cugliari MS, Goh YT, Ionin VA, Mundnich S, Sverdlov AL, Tam C, Ysebaert L
Institution:Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.; Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Journal:Blood Adv. 2022 Sep 27;6(18):5516-5525. doi: 10.1182/bloodadvances.2022007938.

18:Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis.
Authors:Yu TY, Jhou HJ, Chen PH, Lee CH
Institution:Division of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
Journal:Curr Oncol. 2022 Jun 14;29(6):4245-4259. doi: 10.3390/curroncol29060339.

19:CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings.
Authors:Todorovic Z, Todorovic D, Markovic V, Ladjevac N, Zdravkovic N, Djurdjevic P, Arsenijevic N, Milovanovic M, Arsenijevic A, Milovanovic J
Institution:Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.; Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Journal:Curr Oncol. 2022 May 18;29(5):3647-3657. doi: 10.3390/curroncol29050293.

20:Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status.
Authors:Huang Q, Deering KL, Harshaw Q, Leslie LA
Institution:Janssen Scientific Affairs, LLC, Horsham, PA, USA.; John Theurer Cancer Center, Hackensack, NJ, USA.
Journal:Adv Ther. 2022 Jul;39(7):3292-3307. doi: 10.1007/s12325-021-01991-5. Epub 2022 May 24.

21:Patients with CLL have a lower risk of death from COVID-19 in the Omicron era.
Authors:Niemann CU, da Cunha-Bang C, Helleberg M, Ostrowski SR, Brieghel C
Institution:Department of Hematology, Rigshospitalet, Copenhagen, Denmark.
Journal:Blood. 2022 Aug 4;140(5):445-450. doi: 10.1182/blood.2022016147.

22:SOHO State of the Art Updates and Next Questions | Management of Most Difficult Cases of Chronic Lymphocytic Leukemia: Relapse After Both BTK and BCL2 Inhibition and Richter Transformation.
Authors:Burke JM
Institution:Rocky Mountain Cancer Centers, Aurora, CO. Electronic address: john.burke@usoncology.com.
Journal:Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):427-435. doi: 10.1016/j.clml.2022.04.017. Epub 2022 Apr 22.

23:BTK inhibitor selection for chronic lymphocytic leukemia: which drug for which patient?
Authors:Desikan SP, Venugopal S, Ferrajoli A
Institution:Departments of Leukemia, The University of Texas Houston, Texas, USA.
Journal:Expert Rev Hematol. 2022 May;15(5):403-409. doi: 10.1080/17474086.2022.2074393. Epub 2022 May 11.

24:Unusual complications in the management of chronic lymphocytic leukemia.
Authors:Gordon MJ, Ferrajoli A
Institution:MD Anderson Cancer Center, University of Texas, Houston, Texas, USA.
Journal:Am J Hematol. 2022 Nov;97 Suppl 2:S26-S34. doi: 10.1002/ajh.26585. Epub 2022 May 12.

25:A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib.
Authors:Mato AR, Tang B, Azmi S, Yang K, Zhang X, Stern JC, Hedrick E, Huang J, Sharman JP
Institution:Memorial Sloan Kettering Cancer Center, New York. matoa@mskcc.org.; Willamette Valley Cancer Institute / US Oncology Research, Eugene.
Journal:Haematologica. 2022 Nov 1;107(11):2630-2640. doi: 10.3324/haematol.2021.280376.

26:Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T.
Authors:Wiedmeier-Nutor J, Leis J
Institution:Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA. Wiedmeier.julia@mayo.edu.
Journal:Curr Treat Options Oncol. 2022 Jun;23(6):904-919. doi: 10.1007/s11864-022-00953-5. Epub 2022 Apr 18.

27:Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Authors:Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M, Kay NE
Institution:Stanford University, Stanford, CA.; Mayo Clinic, Rochester, MN.
Journal:Blood. 2022 Jul 14;140(2):112-120. doi: 10.1182/blood.2021014960.

28:Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies.
Authors:Rivera D, Ferrajoli A
Institution:Department of Leukemia, The University of Texas-MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 0428, Houston, TX, 77030, USA. aferrajo@mdanderson.org.
Journal:Curr Oncol Rep. 2022 Aug;24(8):1003-1014. doi: 10.1007/s11912-022-01261-9. Epub 2022 Apr 2.

29:New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.
Authors:Iskierka-Jażdżewska E, Obracaj A, Urbaniak M, Robak T
Institution:Department of General Hematology, Copernicus Memorial Hospital, Lodz, Poland. tadeusz.robak@umed.lodz.pl.
Journal:Curr Treat Options Oncol. 2022 Jun;23(6):775-795. doi: 10.1007/s11864-022-00974-0. Epub 2022 Mar 31.

30:Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia.
Authors:Gill S, Vides V, Frey NV, Hexner EO, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, Gaymon AL, Gladney WL, Lacey SF, Lamontagne A, Mato AR, Maus MV, Melenhorst JJ, Pequignot E, Ruella M, Shestov M, Byrd JC, Schuster SJ, Siegel DL, Levine BL, June CH, Porter DL
Institution:Cell Therapy and Transplant Program, Division of Hematology-Oncology and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Journal:Blood Adv. 2022 Nov 8;6(21):5774-5785. doi: 10.1182/bloodadvances.2022007317.

31:Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia.
Authors:Molica S, Tam C, Polliack A
Institution:Department of Hematology, Hull University Teaching Hospitals NHS Trust, Hull, UK.; Department of Hematology, Hadassah-Hebrew-University Medical Center, Jerusalem, Israel.
Journal:Hematol Oncol. 2022 Aug;40(3):313-319. doi: 10.1002/hon.2990. Epub 2022 Mar 23.

32:Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.
Authors:Tettamanti S, Rotiroti MC, Giordano Attianese GMP, Arcangeli S, Zhang R, Banerjee P, Galletti G, McManus S, Mazza M, Nicolini F, Martinelli G, Ivan C, Veliz Rodriguez T, Barbaglio F, Scarfò L, Ponzoni M, Wierda W, Gandhi V, Keating M, Biondi A, Caligaris-Cappio F, Biagi E, Ghia P, Bertilaccio MTS
Institution:Centro Ricerca Tettamanti, Clinica Pediatrica, Universita Milano Bicocca, Osp. San Gerardo/Fondazione MBBM, Monza, Italy.; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Journal:Leuk Lymphoma. 2022 Jul;63(7):1566-1579. doi: 10.1080/10428194.2022.2043299. Epub 2022 Mar 8.

33:Frequency and timing of other primary cancers in patients with chronic lymphocytic leukemia (CLL): a 17-year longitudinal study.
Authors:Akhtar OS, Groman A, Singh A, Ghione P, Lund I, Hernandez-Ilizaliturri FJ, Torka P
Institution:Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Journal:Leuk Lymphoma. 2022 May;63(5):1127-1136. doi: 10.1080/10428194.2021.2012662. Epub 2022 Feb 13.

34:Oral oncolytic treatment for chronic lymphocytic leukemia.
Authors:Harris V, Borlagdan J, Muluneh B
Institution:Pharmacy, 427363Novant Health Presbyterian Medical Centre, 200 Hawthorne Ln, Charlotte, NC, USA 28204.; 15521UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA.
Journal:J Oncol Pharm Pract. 2022 Jun;28(4):935-944. doi: 10.1177/10781552211073906. Epub 2022 Jan 27.

35:First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial.
Authors:Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Novak J, Strugov V, Gill D, Gribben JG, Kwei K, Dai S, Hsu E, Dean JP, Flinn IW
Institution:Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain. cmorenoa@santpau.cat.; Sarah Cannon Research Institute, Nashville, TN, USA.
Journal:Haematologica. 2022 Sep 1;107(9):2108-2120. doi: 10.3324/haematol.2021.279012.

36:Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients.
Authors:Brown JR, Byrd JC, Ghia P, Sharman JP, Hillmen P, Stephens DM, Sun C, Jurczak W, Pagel JM, Ferrajoli A, Patel P, Tao L, Kuptsova-Clarkson N, Moslehi J, Furman RR
Institution:Dana-Farber Cancer Institute, Boston, MA. jennifer_brown@dfci.harvard.edu.; Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY.
Journal:Haematologica. 2022 Jun 1;107(6):1335-1346. doi: 10.3324/haematol.2021.278901.

37:Venetoclax alone or in combination with other regimens treatment achieve deep and sustained remission of relapsed/refractory chronic lymphocytic leukemia: a meta-analysis.
Authors:Tang X, Zou W, Peng P, Bai Y
Institution:Department of Hematology, Mianyang 404 Hospital, Mianyang, 621000, Sichuan Province, China. Sylvia1227@126.com.
Journal:Clin Exp Med. 2022 May;22(2):161-171. doi: 10.1007/s10238-021-00739-3. Epub 2021 Jul 5.

For a FREE PREVIEW of the Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Chronic Lymphocytic Leukemia...
at a Special 20% Discount


Medifocus Guidebook on Chronic Lymphocytic Leukemia

Updated: January 17, 2023
182 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Chronic Lymphocytic Leukemia is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $37.45
  • Less 20% Discount = - $7.10
  • Discounted Price = $30.35(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $31.20
  • Less 20% Discount = - $6.45
  • Discounted Price = $24.75

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

CL941023330

Coupon Expires: March 9, 2023



What Our Customers Are Saying...

"I was recently diagnosed with CLL and searched all over the Web for information. I found the MediFocus Guidebook on Chronic Lymphocytic Leukemia to be a very useful resource. The information about chemotherapy was most important to me as well as recent studies concerning general treatments for this condition. The most valuable information was contained in the extensive references listed which were easy to access with a simple 'mouse' click. You are welcome to use my name as a reference."
G.C.
Coedpoeth, United Kingdom



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2023 Medifocus, Inc. All rights reserved.